The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

Blood. 2018 Jan 25;131(4):464-467. doi: 10.1182/blood-2017-10-809293. Epub 2017 Nov 22.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Lenalidomide / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Immunologic Factors
  • daratumumab
  • Thalidomide
  • pomalidomide
  • Lenalidomide